This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dong, Y. Articles by Ip, C. Search for Related Content PubMed PubMed Citation Articles by Dong, Y. Articles by Ip, C.

Identification of Molecular Targets Associated with Selenium-induced Growth Inhibition in Human Breast Cells Using cDNA Microarrays¹

Department of Experimental Pathology, Roswell Park Cancer Institute, Buffalo, New York 14263 [Y. D., C. S., C. I.], and Department of Nutritional Sciences, University of Wisconsin, Madison, Wisconsin 53706 [H. E. G.]

Past research indicated that methylseleninic acid (MSA) is an excellent tool for investigating the cancer chemopreventive action of selenium in vitro. The present study was designed to examine the cellular and molecular effects of MSA in the MCF10AT1 and MCF10AT3B premalignant human breast cells. After exposure to MSA, both cell lines exhibited a dose- and time-dependent growth-inhibitory response as determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay. Further characterization of cellular and molecular changes was carried out only with the MCF10AT1 cells. Flow cytometry analysis showed that MSA blocked cell cycle progression at the G₀-G₁ phase. Induction of apoptosis was also observed with the use of either the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) or the annexin V binding method. cDNA microarray analyses with cell cycle- and apoptosis-targeted arrays were then applied to profile the gene expression changes mediating these two cellular events. The analyses were conducted at 6 and 12 h of MSA treatment using synchronized cells. The expression signals of 30 genes were found to be significantly altered by MSA. These genes fall into three categories: cell cycle checkpoint controllers (e.g., cyclins, cdcs, cdks, E2F family proteins, and serine/threonine kinases), apoptosis regulatory genes (e.g., Apo-3, c-jun, and cdk5/cyclin D1), and signaling molecules [e.g., mitogen-activated protein (MAP)/extracellular signal-regulated protein kinase (ERK) and phosphatidylinositol 3'-kinase (PI3k) cascade genes]. The expression changes of 15 genes were selected for verification by Western or semiquantitative reverse transcription-PCR analyses. An agreement rate of 60% (9 of 15) was obtained from these confirmation experiments. On the basis of the above findings, tentative signaling pathways mediating the outcome of selenium-induced cell cycle arrest and apoptosis are proposed. The present study thus demonstrated the feasibility of applying cDNA microarray technology in delineating the mechanisms of the action of selenium and in pinpointing molecular targets as potential biomarkers for evaluating the efficacy of selenium intervention.

This article has been cited by other articles:

				X. Zhang and H. Zarbl Chemopreventive Doses of Methylselenocysteine Alter Circadian Rhythm in Rat Mammary Tissue Cancer Prevention Research, July 1, 2008; 1(2): 119 - 127. [Abstract] [Full Text] [PDF]

				Y. Hu, G. H. McIntosh, R. K. Le Leu, R. Woodman, and G. P. Young Suppression of Colorectal Oncogenesis by Selenium-Enriched Milk Proteins: Apoptosis and K-ras Mutations Cancer Res., June 15, 2008; 68(12): 4936 - 4944. [Abstract] [Full Text] [PDF]

				J. Y. Chun, Y. Hu, E. Pinder, J. Wu, F. Li, and A. C. Gao Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter Mol. Cancer Ther., September 1, 2007; 6(9): 2572 - 2580. [Abstract] [Full Text] [PDF]

				J.-T. Hwang, Y. M. Kim, Y.-J. Surh, H. W. Baik, S.-K. Lee, J. Ha, and O. J. Park Selenium Regulates Cyclooxygenase-2 and Extracellular Signal-Regulated Kinase Signaling Pathways by Activating AMP-Activated Protein Kinase in Colon Cancer Cells. Cancer Res., October 15, 2006; 66(20): 10057 - 10063. [Abstract] [Full Text] [PDF]

				N. Joshi, L. L. Johnson, W.-Q. Wei, C. C. Abnet, Z.-W. Dong, P. R. Taylor, P. J. Limburg, S. M. Dawsey, E. T. Hawk, Y.-L. Qiao, et al. Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk chinese population. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 1046 - 1047. [Abstract] [Full Text] [PDF]

				R. Jagadeeswaran, P. C. Ma, T. Y. Seiwert, S. Jagadeeswaran, O. Zumba, V. Nallasura, S. Ahmed, R. Filiberti, M. Paganuzzi, R. Puntoni, et al. Functional Analysis of c-Met/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma Cancer Res., January 1, 2006; 66(1): 352 - 361. [Abstract] [Full Text] [PDF]

				Y. M. Shah, M. Al-Dhaheri, Y. Dong, C. Ip, F. E. Jones, and B. G. Rowan Selenium disrupts estrogen receptor {alpha} signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells Mol. Cancer Ther., August 1, 2005; 4(8): 1239 - 1249. [Abstract] [Full Text] [PDF]

				S. O. Lee, N. Nadiminty, X. X. Wu, W. Lou, Y. Dong, C. Ip, S. A. Onate, and A. C. Gao Selenium Disrupts Estrogen Signaling by Altering Estrogen Receptor Expression and Ligand Binding in Human Breast Cancer Cells Cancer Res., April 15, 2005; 65(8): 3487 - 3492. [Abstract] [Full Text] [PDF]

				S. Cao, F. A. Durrani, and Y. M. Rustum Selective Modulation of the Therapeutic Efficacy of Anticancer Drugs by Selenium Containing Compounds against Human Tumor Xenografts Clin. Cancer Res., April 1, 2004; 10(7): 2561 - 2569. [Abstract] [Full Text] [PDF]

				H. Zhao, M. L. Whitfield, T. Xu, D. Botstein, and J. D. Brooks Diverse Effects of Methylseleninic Acid on the Transcriptional Program of Human Prostate Cancer Cells Mol. Biol. Cell, February 1, 2004; 15(2): 506 - 519. [Abstract] [Full Text] [PDF]

				Y. Dong, S. O. Lee, H. Zhang, J. Marshall, A. C. Gao, and C. Ip Prostate Specific Antigen Expression Is Down-Regulated by Selenium through Disruption of Androgen Receptor Signaling Cancer Res., January 1, 2004; 64(1): 19 - 22. [Abstract] [Full Text] [PDF]

				H. Swede, Y. Dong, M. Reid, J. Marshall, and C. Ip Cell Cycle Arrest Biomarkers in Human Lung Cancer Cells After Treatment with Selenium in Culture Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1248 - 1252. [Abstract] [Full Text]

				M. Q. Kemp, B. D. Jeffy, and D. F. Romagnolo Conjugated Linoleic Acid Inhibits Cell Proliferation through a p53-Dependent Mechanism: Effects on the Expression of G1-Restriction Points in Breast and Colon Cancer Cells J. Nutr., November 1, 2003; 133(11): 3670 - 3677. [Abstract] [Full Text] [PDF]

				T. A. Hornberger, T. J. McLoughlin, J. K. Leszczynski, D. D. Armstrong, R. R. Jameson, P. E. Bowen, E.-S. Hwang, H. Hou, M. E. Moustafa, B. A. Carlson, et al. Selenoprotein-Deficient Transgenic Mice Exhibit Enhanced Exercise-Induced Muscle Growth J. Nutr., October 1, 2003; 133(10): 3091 - 3097. [Abstract] [Full Text] [PDF]

				Y. Dong, H. Zhang, L. Hawthorn, H. E. Ganther, and C. Ip Delineation of the Molecular Basis for Selenium-induced Growth Arrest in Human Prostate Cancer Cells by Oligonucleotide Array Cancer Res., January 1, 2003; 63(1): 52 - 59. [Abstract] [Full Text] [PDF]

				G. P. Sergeant, R. J. Large, E. A. H. Beckett, C. M. McGeough, S. M. Ward, and B. Horowitz Microarray comparison of normal and W/Wv mice in the gastric fundus indicates a supersensitive phenotype Physiol Genomics, October 2, 2002; 11(1): 1 - 9. [Abstract] [Full Text] [PDF]